Sifrol er indiceret til symptomatisk behandling af moderat til svær idiopatisk Restless Legs Syndrome i doser optil 0, 54 mg base (0, 75 mg salt) (se pkt.
In view of the extension of indication to Restless Legs Syndrome, the periodic safety update reports will be submitted every six months during two years, once a year for the following two years and thereafter at three-yearly intervals.